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Abstract. 
 
Signaling by members of the epidermal 
growth factor receptor family plays an important role in 
breast development and breast cancer. Earlier work 
suggested that one of these receptors, ErbB4, is cou-
pled to unique responses in this tissue. To determine the 
function of ErbB4 signaling in the normal mouse mam-
mary gland, we inactivated ErbB4 signaling by express-
ing a COOH terminally deleted dominant-negative
 
allele of 
 
ErbB4
 
 (
 
ErbB4
 
D
 
IC
 
) as a transgene in the mam-
mary gland. Despite the expression of 
 
ErbB4
 
D
 
IC
 
 from 
puberty through later stages of mammary development, 
an 
 
ErbB4
 
D
 
IC
 
-speciﬁc phenotype was not observed un-
til mid-lactation. At 12-d postpartum, lobuloalveoli ex-
pressing ErbB4
 
D
 
IC protein were condensed and lacked 
normal lumenal lactation products. In these lobuloalve-
oli, 
 
b
 
-casein mRNA, detected by in situ hybridization, 
was normal. However, whey acidic protein mRNA was 
reduced, and 
 
a
 
-lactalbumin mRNA was undetectable. 
Stat5 expression was detected by immunohistochemis-
try in ErbB4
 
D
 
IC-expressing tissue. However, Stat5 was 
not phosphorylated at Y694 and was, therefore, proba-
bly inactive. When expressed transiently in 293T cells, 
ErbB4 induced phosphorylation of Stat5. This phos-
phorylation required an intact Stat5 SH2 domain. In 
summary, our results demonstrate that ErbB4 signaling 
is necessary for mammary terminal differentiation and 
Stat5 activation at mid-lactation.
Key words: ErbB4 • Stat5 • dominant-negative mu-
tant • transgenic mice • mammary gland development
 
A
 
BERRANT
 
 signaling activity by members of the epider-
mal growth factor receptor (EGFR)
 
1
 
 family of ty-
rosine kinases frequently occurs in human cancer.
The family consists of the EGFR (HER), ErbB2 (HER2/
Neu), ErbB3 (HER3), and ErbB4 (HER4). These recep-
tors are activated by binding of growth factors in the
EGFR family, which are encoded by at least nine genes.
The ligand-activated receptors can signal either through
homodimerization or through heterodimerization with
other EGFR family members. Each receptor/ligand com-
bination has the potential to recruit and activate a unique
set of interacting proteins, thereby initiating signaling cas-
cades which culminate in distinct cellular responses (re-
viewed in Alroy and Yarden, 1997; Riese and Stern, 1998).
Overexpression of three of these receptors, EGFR,
ErbB2, and ErbB3, is associated with carcinogenesis. For
example, amplification of 
 
EGFR
 
 and 
 
ErbB2
 
, or both, oc-
curs in a large subset of breast carcinomas, and is associ-
ated with poor prognosis or the presence of negative prog-
nostic indicators (reviewed in Hynes and Stern, 1994;
Dickson and Lippman, 1995). Elevated levels of ErbB3
have been reported in 22–55% of breast carcinomas (Lem-
oine et al., 1992; Quinn et al., 1994; Bobrow et al., 1997;
Naidu et al., 1998). In contrast, ErbB4 is normally found
in differentiating tissues (Srinivasan et al., 1998), ErbB4
overexpression in breast cancer is associated with favor-
able prognostic factors (Bacus et al., 1994, 1996; Knowlden
et al., 1998), and ErbB4 expression may be selectively ex-
tinguished during breast tumor progression (Srinivasan et
al., 1998). These results suggest that ErbB4 is coupled to a
differentiation response, rather than the proliferation re-
sponse associated with the other three EGFR family mem-
bers in mammary epithelium.
The role of ErbB4 in mammary differentiation is further
supported by patterns of receptor expression and activa-
tion during normal mouse mammary gland development.
Unlike EGFR and ErbB2, which are expressed and acti-
vated during puberty (Schroeder and Lee, 1998; Sebastian
et al., 1998), ErbB4 expression is first strong in mature fe-
males (Schroeder and Lee, 1998). Although ErbB4 is ex-
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1. 
 
Abbreviations used in this paper:
 
 EGFR, epidermal growth factor recep-
tor; LPrlR, long prolactin receptor isoform; MMTV, mouse mammary tu-
mor virus; NRG1, neuregulin-1; PrlR, prolactin receptor; SPrlR, short
prolactin receptor isoform; Stat, signal transducers and activators of tran-
scription; TGF
 
a
 
, transforming growth factor 
 
a
 
;
 
 WAP, whey acidic pro-
tein. 
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pressed strongly throughout pregnancy, ErbB4 tyrosine
phosphorylation, an indicator of active signaling, was only
first detected at late pregnancy, when epithelial differenti-
ation and secretory activity predominate over prolifera-
tion, and peaked during lactation, when mammary epithe-
lium undergo terminal differentiation (Schroeder and Lee,
1998). Moreover, we previously demonstrated that the
ErbB3/ErbB4 ligand neuregulin-1 (NRG1), but not the
EGFR ligand transforming growth factor 
 
a
 
 (TGF
 
a
 
), in-
duces epithelial differentiation, with expression of the
milk protein 
 
b
 
-casein, when implanted in mammary glands
of virgin mice (Jones et al., 1996). Finally, a role for NRG1
in mammary differentiation is consistent with high levels
of NRG1 expression observed during pregnancy (Yang et al.,
1995).
Stat5, a member of the signal transducers and activators
of transcription (Stat) family, also appears to play an im-
portant role in mammary differentiation. Stat5 was ini-
tially identified as mammary gland factor in nuclear ex-
tracts from lactating mice (Wakao et al., 1992, 1994).
Expression, activation by phosphorylation, and nuclear
translocation of Stat5 are tightly linked to mammary dif-
ferentiation (Kazansky et al., 1995; Liu et al., 1996a). Con-
sistent with these results, both Stat5a and Stat5b are re-
quired for normal milk gene expression and lactation at
parturition (Liu et al., 1996b; Teglund et al., 1998). Al-
though Stat5 was first identified as a prolactin-regulated
transducer, members of the EGF family of growth factors
recently have been shown to activate Stat5 through ty-
rosine phosphorylation of the Stat5 polypeptide (Ruff-
Jamison et al., 1995; David et al., 1996; Garcia et al., 1997;
Richer et al., 1998; Olayioye et al., 1999). These latter re-
sults raise the possibility that Stat5 can be activated by
EGFR family members during mammary differentiation.
Although the timing of expression of ErbB4 ligands and
activation of ErbB4 suggest that ErbB4 regulates differen-
tiation, the function of ErbB4 signaling during mammary
gland development is not known. To identify the role of
ErbB4 signaling during breast development, we inacti-
vated endogenous ErbB4 signaling in the mouse mam-
mary gland through transgenic expression of a mutant
ErbB4 with dominant-negative activity. The results iden-
tify a role for ErbB4 in terminal differentiation of mam-
mary epithelium, including activation of the important me-
diator of mammary differentiation, Stat5.
 
Materials and Methods
 
Plasmids
 
pMMTV-ErbB4
 
D
 
IC contains a truncated human ErbB4 cDNA in which
sequences encoding ErbB4 up to P705 are fused to sequences encod-
ing tandem Flag epitope tags (Kodak), immediately followed by two
stop codons. The coding sequences are under regulatory control of a
mouse mammary tumor virus (MMTV) long terminal repeat. The vector
pMMTV-SV40-Bssk (pMMTV-GAL4/236-SV40 minus the 
 
GAL4
 
/236
gene; Ornitz et al., 1991; generously provided by Dr. Philip Leder, Har-
vard Medical School, Boston, MA) was first modified to generate the vec-
tor pMMTV-Aat using the AatII linker 5
 
9
 
-ACTAGTGACGTCA at the
unique SpeI site. pMMTV-ErbB4
 
D
 
IC was produced by trimolecular liga-
tion joining the HindIII (site filled with T4 DNA polymerase)-EcoRI di-
gested pMMTV-Aat; the 3
 
9
 
 
 
z
 
2.1 Kb SalI (site filled with T4 DNA poly-
merase)-SpeI fragment from pLXSN-ErbB4 (Riese et al., 1995); and the
285-bp SpeI-EcoRI digested PCR product generated from pLXSN-ErbB4
 
using the forward primer upstream of the unique SpeI site 5
 
9
 
-CCCAC-
TAGTCATGAC (nt 1905–1919; Plowman et al., 1993) and the reverse
primer with an EcoRI linker 5
 
9
 
-CGGAATTCTTATTACTTGTCATC-
GTCGTCTTGTAGTCCTTGTCATCGTCGTCCTTGTAGTCGGGTG-
CTGTGCC-3
 
9
 
 (nt 2138–2127; Plowman et al., 1993).
The riboprobe template pBl-ErbB4
 
D
 
IC was produced by subclon-
ing the 285-bp SpeI-EcoRI digested PCR product described above
into pBluescript I S/K (Stratagene). Riboprobe template pBl-
 
b
 
-casein
was generated by subcloning the 170-bp HindIII-StuI fragment from
pFLAG1-
 
b
 
-casein (generously supplied by Dr. Nancy Hynes, Friedrich
Miescher Institute, Basel, Switzerland) into HindIII-SmaI digested
pBluescript I S/K. The riboprobe template pBl-WAP, for quantifying
mouse whey acidic protein (WAP) RNA, was generated by reverse tran-
scriptase PCR (RT-PCR) of mouse mammary gland RNA isolated from a
female at 3-d postpartum using the downstream primer 5
 
9
 
-CTATCTG-
CATTGGGCACGGCCCGG (nt 319–296; Hennighausen and Sippel,
1982). The cDNA was amplified by PCR using the downstream primer
specified above, and the upstream primer 5
 
9
 
-CCTCATCAGCCTTGT-
TCTTGGCCT (nt 24–47; Hennighausen and Sippel, 1982). The 295-bp
PCR product was made blunt with T4 DNA polymerase and subcloned
into the SmaI site of pBluescript I S/K. The riboprobe template pBl-
 
a
 
-lac-
talbumin, was generated by RT-PCR with the downstream primer 5
 
9
 
-
GGGCTTCTCACAACGCCACTGTTC (nt 439–416; Vilotte and Soul-
ier, 1992) and the upstream primer 5
 
9
 
-CATAGATGGCTATCAAG-
GCATCTC (nt 114–137; Vilotte and Soulier, 1992). The PCR product was
digested with HincII-HindIII and the resultant 214-bp fragment was sub-
cloned into pBluescript I K/S.
 
Generation of MMTV-ErbB4
 
D
 
IC Transgenic Mice
 
Vector sequences for microinjection were separated from pMMTV-
ErbB4
 
D
 
IC by digestion at unique AatII-XhoI sites. The 
 
z
 
6.2-kb fragment
containing the MMTV LTR, a 600-bp 5
 
9
 
 untranslated region of c-Ha-
 
ras
 
,
the truncated human ErbB4 cDNA with COOH-terminal tandem Flag
epitope tags, and simian virus 40 3
 
9
 
 mRNA processing signals, was puri-
fied by agarose gel electrophoresis. The purified DNA fragment was mi-
croinjected into single-cell B6SJL/F2 zygotes at a concentration of 12 
 
m
 
g/ml
in 10 mM Tris, pH 7.5, 0.1 mM EDTA (by Ms. Carole Pelletier under the
direction of Dr. David Brownstein at the Transgenic Mouse Shared Re-
source of the Yale University School of Medicine, New Haven, CT).
 
Identification of Transgenic Mice by PCR
 
Transgenic mice were identified by PCR of DNA isolated from tail biop-
sies. DNA purification, PCR conditions, and controls have been described
previously (Jones and Stern, 1999). Primers for the amplification of a 360-bp
MMTV-ErbB4
 
D
 
IC fragment were 5
 
9
 
-CAAGTATGCTGATCCAGA-
TCGGGA (nt 1827–1850 from ErbB4 open reading frame; Plowman et
al., 1993) and 5
 
9
 
-GAATTCTTATTACTTGTCATCGTC, which hybrid-
izes to the 3
 
9
 
-terminal Flag epitope tag and unique EcoRI site of MMTV-
ErbB4
 
D
 
IC.
 
RNA Isolation and RNase Protection Assay
 
RNA was isolated from the number 4 inguinal mammary gland by TRIzol
extraction (GIBCO BRL). Riboprobe synthesis and purification, and
RNA analysis using the RPA II ribonuclease protection assay kit (Am-
bion) were performed as described (Jones and Stern, 1999).
 
Tissue Preparation for Histological Analysis
 
For hematoxylin/eosin staining, immunohistochemistry, and in situ hy-
bridization, a portion of the number four inguinal mammary gland was
spread onto a glass microscope slide and fixed in freshly prepared 4%
paraformaldehyde in PBS (15 mM Na
 
2
 
HPO
 
4
 
, 1.5 mM KH
 
2
 
PO
 
4
 
, 137 mM
NaCl, 3 mM KCl, pH 7.2) overnight at 4
 
8
 
C. The fixed tissue was embed-
ded in paraffin and 6-
 
m
 
m sections were dried onto gelatin-coated slides us-
ing standard procedures.
 
Immunohistochemistry
 
Immunohistochemical detection of Flag-tagged ErbB4
 
D
 
IC and Stat5 was
performed as described elsewhere (Jones and Stern, 1999) with the fol-
lowing modifications. For Flag immunohistochemistry, the primary anti-
body was rabbit anti-Flag probe (Santa Cruz) diluted to 0.67 
 
m
 
g/ml and
secondary antibody was biotinylated goat anti–rabbit diluted to 15 
 
m
 
g/ml 
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(Vector Labs, Inc.). Negative controls included similarly treated mam-
mary gland paraffin sections from nontransgenic siblings and affinity-puri-
fied rabbit IgG diluted to 0.67 
 
m
 
g/ml as the primary antibody. For Stat5
immunohistochemistry, primary antibody was rabbit anti-Stat5 LH743
(Liu et al., 1996a; generously provided by Dr. Lothar Hennighausen, Na-
tional Institutes of Health, Bethesda, MD) diluted 1/600 and secondary
antibody was biotinylated goat anti–rabbit diluted to 15 
 
m
 
g/ml (Vector
Labs, Inc.). Sections were blocked and all antibodies were diluted in PBS
containing 10% goat serum. Similarly treated mammary gland paraffin
sections from nontransgenic mice at 3- and 18-d postpartum served as
Stat5 positive and negative controls, respectively. An additional Stat5 neg-
ative control was rabbit serum (Pierce Chemical Co.) diluted 1/600 as the
primary antibody.
For immunohistochemical detection of Stat5 phosphorylated at Y694,
sections were pretreated to expose phosphorylated Stat5 epitopes. Depar-
affinized sections were treated with 1 mg/ml of buffered trypsin (Sigma
Chemical Co.) for 20 min at 37
 
8
 
C. Endogenous peroxidase activity was in-
activated by incubating the sections in 0.5% H
 
2
 
O
 
2
 
 in PBS for 15 min at
room temperature. The sections were incubated in 2 N HCl for 1 h at
room temperature followed by two washes in 100 mM borate buffer, pH
8.5, for 5 min per wash. The sections were treated with 0.2% NP-40 for 30
min at room temperature. Between each treatment the sections were
washed twice in PBS for 5 min per wash. The remainder of the procedure
was performed as described elsewhere (Jones and Stern, 1999) with the
following modifications. Primary antibody was rabbit antiphospho-Stat5
(Zymed Labs, Inc.) diluted to 10 
 
m
 
g/ml and secondary antibody was bio-
tinylated goat anti–rabbit diluted to 15 
 
m
 
g/ml (Vector Labs, Inc.). PBS
containing 10% goat serum was used to block sections and dilute antibod-
ies. For peptide blocking experiments, phospho-Stat5 antibody was di-
luted to 10 
 
m
 
g/ml in PBS containing 10% goat serum and 400 
 
m
 
g/ml of
phospho-Stat5 peptide immunogen (Zymed Labs, Inc.). The antibody/
peptide solution was incubated for 15 min at room temperature before ap-
plication to the sections. Positive and negative controls for phospho-Stat5
immunohistochemistry were similarly treated paraffin sections from mam-
mary glands at 3- and 18-d postpartum, respectively. Affinity-purified rab-
bit IgG diluted to 10 
 
m
 
g/ml as the primary antibody also served as a nega-
tive control.
Immunostained sections were lightly counterstained in hematoxylin
(Polysciences Inc.) or methyl green (Vector Labs, Inc.) according to the
manufacturer’s instructions, dehydrated in EtOH, cleared in xylene, and
coverslipped with Permount (Fisher Scientific Co.).
 
Riboprobe Synthesis and Purification
 
Buffers used for riboprobe synthesis and transcript purification were gen-
erally pretreated with DEPC. For in situ hybridization experiments, DNA
template was linearized for sense and antisense riboprobe synthesis and
contaminating ribonucleases were inactivated by proteinase treatment at
37
 
8
 
C for 1 h in 10 mM Tris, pH 8.0, 50 mM NaCl, 5 mM EDTA, 0.6%
SDS, and 150 
 
m
 
g/ml proteinase K. In vitro transcription and subsequent
DNase treatment were performed using a MAXIscript in vitro transcrip-
tion kit (Ambion) with 1 
 
m
 
g of template DNA and 130 
 
m
 
Ci of 
 
35
 
S-UTP
(DuPont-NEN) exactly as described by the manufacturer. Transcripts
were suspended to 200 
 
m
 
l in a final concentration of 10 mM DTT (Sigma
Chemical Co.), 300 mM NaOAc, and 20 
 
m
 
g of t-RNA, and purified by
EtOH precipitation with 2 M NH
 
4
 
OAc. The precipitated RNA was
washed extensively in 70% EtOH, resuspended into 10 mM DTT, and
precipitated and washed a second time. The final RNA pellet was resus-
pended into 10 mM DTT.
 
In Situ Hybridization
 
In situ hybridization was performed on 6-
 
m
 
m paraffin sections of mam-
mary glands from female mice at 1- and 12-d postpartum using 
 
35
 
S-UTP
labeled riboprobes. Sections were deparaffinized in xylene, washed in
100% EtOH, and defatted by incubating with chloroform for 5 min. The
sections were hydrated through a descending EtOH series and washed in
PBS for 5 min. The tissue was etched in 2 
 
m
 
g/ml of protease K in PBS for
10 min at 37
 
8
 
C and rinsed in PBS. Tissue sections were postfixed in 4%
paraformaldehyde in PBS for 10 min, quenched with 0.2% glycine in PBS
for 5 min, and washed in PBS for 5 min. Nonspecific binding sites were
blocked by incubating the sections for 10 min in 100 mM triethanolamine
(Sigma Chemical Co.), pH 8.0, 0.9% NaCl, containing 0.25% acetic anhy-
dride (Sigma Chemical Co.). The slides were washed in 2
 
3
 
 SSC (20
 
3
 
 SSC 
 
5
 
3 M NaCl, 0.3 M sodium citrate, pH 7.0) for 5 min, dehydrated through an
 
ascending ethanol series, treated with chloroform for 5 min, washed two
times with 100% ethanol for 2 min per wash, and air dried.
The hybridization mixture contained 10 mM Tris, pH 7.5, 600 mM
NaCl, 2 mM EDTA, 10 mM DTT, 1
 
3
 
 Denhardt’s (Sigma Chemical Co.),
500 
 
m
 
g/ml total yeast RNA (Ambion), 100 
 
m
 
g/ml poly-A (Pharmacia Bio-
tech, Inc.), 100 mg/ml dextran sulfate (Sigma Chemical Co.), 50% deion-
ized formamide (Ambion), and 4 
 
3 
 
10
 
4
 
 cpm/
 
m
 
l of 
 
35
 
S-UTP–labeled ribo-
probe, and was heated at 80
 
8
 
C for 10 min immediately before use. To
each section, 50 
 
m
 
l of hybridization mixture was applied, the sections
were overlaid with parafilm coverslips, and hybridized at 50
 
8
 
C for 16 h in
a humid chamber containing 10 mM Tris, pH 7.5, 600 mM NaCl, 2 mM
EDTA, and 50% formamide (Sigma Chemical Co.). After hybridization,
the parafilm coverslips were removed and the slides were washed twice at
low stringency for 15 min per wash at 50
 
8
 
C in 2
 
3
 
 SSC, 50% formamide,
and 0.1% 
 
b
 
-mercaptoethanol. Nonhybridized probe was digested by
placing the slides in 10 mM Tris, pH 8.0, 500 mM NaCl, containing 20 
 
m
 
g/
ml of RNase A (Sigma Chemical Co.) for 30 min at 37
 
8
 
C. The low strin-
gency washes were repeated and the slides were washed an additional
two times in 0.1
 
3
 
 SSC and 1% 
 
b
 
-mercaptoethanol at 50
 
8
 
C for 15 min per
wash. The slides were dehydrated through an ascending ethanol series,
with a final concentration of 600 mM NaCl included in ethanol solutions
under 80%, and air dried. Dried slides were dipped in Kodak NTB-2 nu-
clear track emulsion diluted 1:1 with ddH
 
2
 
O at 45
 
8
 
C, and were exposed at
4
 
8
 
C in light-tight slide boxes containing silica gel desiccant packets
(Sigma Chemical Co.). Before developing, the slides were warmed to
room temperature and developed in Kodak D-19 developer for 2.5 min,
washed in ddH
 
2
 
O for 30 s, fixed in Kodak fixer for 3 min, and washed in
running tap water for 15 min. The sections were lightly counterstained
with hematoxylin using the same procedure described for immunohis-
tochemistry.
 
Cell Transfections
 
293T cells were transfected using FuGENE6 transfection reagent (Boeh-
ringer Mannheim Corp.) according to the manufacturer’s instructions. In
brief, cells 25% confluent in 100-mm tissue culture dishes were transfected
with 500 
 
m
 
l of growth medium without serum, containing 10 
 
m
 
l of
FuGENE6 and 2 
 
m
 
g of each plasmid, for a total of 4 
 
m
 
g. The cells were in-
cubated with transfection mixture for 48 h in a humidified incubator at
37
 
8
 
C with 5% CO
 
2
 
. Plasmid pLXSN (Miller and Rosman, 1989) served as
a vector control for ErbB4 transfections. pLXSN-ErbB4 expresses human
ErbB4 (Riese et al., 1995). pEF-neo served as a vector control for Stat5a
transfections. pEF-Stat5a (Welte et al., 1999) encodes mouse Stat5a
cDNA. pEF-Stat5/Y694F (Welte et al., 1999) is pEF-Stat5a with a tyrosine
to phenylalanine mutation at residue 694, which abrogates Stat5 nuclear
localization and DNA binding (Gouilleux et al., 1994). pEF-Stat5/R618V
is pEF-Stat5a with an arginine to valine mutation at residue 618, which ab-
lates SH2 function (Schindler and Darnell, 1995). This mutation was cre-
ated using QuikChange Site-Directed Mutagenesis Kit (Stratagene) and
the oligonucleotide primer 5
 
9
 
-GCGAAAGCAGTCGACGGATTCGT-
GAAGCCACAG.
 
Immunoprecipitation from Cell Extracts and Western 
Blot Analysis
 
Transfected 293T cells were lysed in 2.0 ml of ice-cold EBC buffer (50 mM
Tris, pH 7.5, 120 mM NaCl, 0.5% NP-40, with 1
 
3
 
 Complete protease in-
hibitor cocktail [Boehringer Mannheim Corp.], 1 mM phenylmethylsulfo-
nyl fluoride, and 1 mM pervanadate) on ice for 10 min. The cell lysates
were cleared by centrifugation in a SS-34 rotor at 5,000 rpm for 15 min at
4
 
8
 
C. Immunoprecipitation of ErbB4 and Stat5a from 500 
 
m
 
l of lysate was
performed by adding 50 
 
m
 
l of preswollen protein A–Sepharose (Pharma-
cia Biotech, Inc.) and 2 
 
m
 
g of anti-ErbB4 (C-18; Santa Cruz) or 2 
 
m
 
g of
anti-Stat5b (C-17; Santa Cruz; Stern et al., 1986). Precipitated proteins
were resolved by SDS-PAGE on a 7.5% acrylamide gel and the resolving
gel was transferred to Trans-Blot 0.45-
 
m
 
m nitrocellulose (Bio-Rad Labo-
ratories) using standard procedures. Western blot analysis was performed
as described previously (Stern et al., 1986). For detection of phosphoty-
rosine containing proteins, mAb 4G10 (Upstate Biotechnology Inc.) was
diluted to 1 
 
m
 
g/ml, followed by sheep anti–mouse conjugated with HRP
(Nycomed Amersham Inc.) diluted 1:3,000. For detection of Stat5a phos-
phorylated at Y694, rabbit antiphospho-Stat5 (Zymed Labs, Inc.) was di-
luted to 0.5 
 
m
 
g/ml; for detection of ErbB4, rabbit polyclonal ErbB4 (C-18)
was diluted to 0.2 
 
m
 
g/ml; and for detection of Stat5, rabbit polyclonal
Stat5b (C-17) was diluted to 0.2 
 
m
 
g/ml. The secondary antibody for rabbit 
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primary antibodies was donkey anti–rabbit conjugated with HRP (Ny-
comed Amersham Inc.) diluted 1:3,000. Signal was detected using Super-
Signal West Pico chemiluminescence substrate (Pierce Chemical Co.) ac-
cording to the manufacturer’s instructions.
Results
Transgenic Mice Derived from MMTV-ErbB4DIC
Since the embryonic lethality of ErbB4 gene disruption
precludes characterization of postnatal mammary devel-
opment (Gassmann et al., 1995), we instead used a domi-
nant-negative strategy to inactivate ErbB4 in the mam-
mary gland. For this purpose, ErbB4 coding sequences
encoding a receptor lacking the cytoplasmic domain were
placed under the regulatory control of the MMTV pro-
moter. pMMTV-ErbB4DIC encodes a protein of z120 kD,
as determined by anti-Flag Western blot analysis of sta-
bly transfected FR3T3 cells (data not shown). Expression
of pMMTV-ErbB4DIC inhibits EGF-stimulated tyrosine
phosphorylation of the endogenous EGFR, verifying that,
like cytoplasmic deletion mutants of other receptor tyrosine
kinases, ErbB4DIC has dominant-negative activity (data
not shown). The in vivo specificity of pMMTV-ErbB4DIC
dominant-negative activity is described in the Discussion.
To determine the effect of dominant-negative ErbB4 ac-
tivity within the developing mammary gland, transgenic
mice were derived by injecting MMTV-ErbB4DIC DNA
into the pronuclei of fertilized one-cell zygotes from
B6SJL/F2 mice. 19 founders with transgene integration
(identified by PCR) were crossed into an FVB strain, and
transgene expression by the F2 female offspring was deter-
mined by RNase protection analysis. Transgene expres-
sion was detected in mammary glands of five week-old
female offspring from six different founders (data not
shown). The highest levels of transgene expression were
observed in the offspring of founders 5963 and 5997. Phe-
notypic analysis of mammary glands from mice expressing
ErbB4DIC was performed on F3 females derived by cross-
ing founder line 5963 F2 mice with FVB strain mice. The
phenotype of line 5963 was confirmed by analysis of the
second founder line, 5997.
Expression of the MMTV-ErbB4DIC Transgene in the 
Mammary Gland
The temporal expression pattern of ErbB4DIC RNA in
the mammary gland was determined by RNase protection
assay (Fig. 1). The riboprobe hybridizes to the extreme 39
end of the ErbB4DIC transgene, including unique se-
quences encoding the tandem Flag epitope tags, resulting
in a protected fragment of 285 bp (Fig. 1, lanes 4–16).
Transgene expression was first detected in prepubescent
females at 3 wk and expression levels increased slightly
with age, reaching maximal expression in the mature nul-
liparous mammary gland at 10 wk (Fig. 1, lanes 4–6). The
apparent decrease in expression at 19 wk (Fig. 1, lane 7)
was not observed in other experiments. Expression levels
were similar from early to mid-pregnancy (Fig. 1, lanes 8
and 9), increased at late pregnancy (lane 10), were highest
at 1- and 3-d postpartum (Fig. 1, lanes 11 and 12), and
were reduced from 12-d postpartum (Fig. 1, lane 13)
through weaning (Fig. 1, lanes 14–16).
ErbB4DIC Protein Expression Is Associated with 
Condensed Lobuloalveoli during Lactation
To determine the effects of ErbB4DIC expression on fe-
male mammary gland development, wholemounts and his-
tological sections were examined from virgin mice at 3, 5,
6, 8, 10, and 19 wk of age; during early (12 d), mid- (16 d),
and late (19 d) pregnancy; after parturition at days 3, 6, 9,
12, 15, or 18; and 2–4 d after weaning. At least three mice
were analyzed at each time point. Despite the extensive
time frame for transgene expression, and the fact that ex-
pression was highest shortly after parturition (Fig. 1), the
only identifiable phenotypes were detected on day 12
postpartum. The fat pad of a nontransgenic mouse at 12-d
postpartum is completely invested with engorged lobuloal-
veoli displacing stromal adipose cells. Secretory activity is
demonstrated by lumens lined with protruding secretory
epithelium (Fig. 2 A, arrow). Engorged active secretory
lobuloalveoli were also observed in ErbB4DIC-expressing
mice at 12-d postpartum (Fig. 2 B, arrow). In some trans-
genic mice (3 out of 5 examined), however, a subpopula-
tion of lobuloalveoli failed to expand and contained an un-
usually high level of lumenal secretory lipids (Fig. 2 B,
asterisk). Adipose cells were still abundant in this region
of the mammary gland fat pad. The condensed lobuloal-
veoli resembled undifferentiated lobuloalveoli that are
normally predominant during late pregnancy. We next
used anti-Flag immunohistochemistry to determine if
the condensed lobuloalveoli expressed the Flag-tagged
ErbB4DIC transgene. Intense cytoplasmic immunostain-
ing of epithelium within condensed lobuloalveoli was ob-
served (Fig. 2 D, asterisks). Anti-Flag immunostaining was
not observed in distended lobuloalveoli in the same tissue
sections (Fig. 2 D, arrow). The lack of detectable trans-
gene expression in this subpopulation of lobuloalveoli may
Figure 1. Expression analysis of ErbB4DIC RNA in develop-
mentally staged mammary glands. RNA (20 mg) isolated from
the number 4 inguinal mammary gland was hybridized with 32P-
labeled antisense riboprobe corresponding to the COOH-termi-
nal 285-bp of ErbB4DIC, including sequences encoding the
tandem Flag epitope tags, and subjected to RNase protection
analysis (upper panel). Negative controls included 20 mg each of
tRNA and RNA from a nontransgenic sibling at 1-d postpartum
(control). A probe that hybridizes to b-actin sequences was in-
cluded to control for RNA integrity and to confirm that equiva-
lent amounts of RNA were added to each reaction (lower panel).
Protected fragments corresponding to ErbB4DIC and b-actin are
indicated.Jones et al. ErbB4 Activates Stat5 during Lactation 81
be a result of variegated transgene expression. Variegated
promoter expression within the mouse mammary gland
has been reported for several mammary specific promot-
ers, including the MMTV LTR promoter used in this study
(Faerman et al., 1995; Deckard-Janatpour et al., 1997;
Jones and Stern, 1999).
Although the alveolar condensation associated with
high ErbB4DIC expression might be caused by selective
growth inhibition or apoptosis, neither BrdU incorpora-
tion experiments, nor TUNEL analysis revealed differ-
ences between the phenotypically normal and condensed
lobuloalveolar populations in ErbB4DIC animals (data
not shown). These results suggest instead that ErbB4DIC
expression inhibits normal lobuloalveolar development
and function at 12-d postpartum.
ErbB4DIC Expression Inhibits Milk Gene Expression
ErbB4DIC expression at 12-d postpartum impaired lobu-
loalveolar development, resulting in condensed alveolar
structures with pronounced lipid secretory activity. These
structures resembled normal undifferentiated lobuloalve-
oli observed at late pregnancy and parturition. To deter-
mine if the ErbB4DIC-expressing lobuloalveoli were lacta-
tionally active, we performed in situ hybridization using
antisense riboprobes specific for the milk genes b-casein,
WAP, and a-lactalbumin. Serial paraffin sections contain-
ing both normal expanded lobuloalveolar structures and
condensed lobuloalveoli were examined (Fig. 3 A, arrow
and asterisks, respectively). ErbB4DIC expression within
condensed lobuloalveoli was confirmed by anti-Flag im-
munohistochemistry (Fig. 3 B, asterisks). The sense probes
for b-casein, WAP, and a-lactalbumin yielded similar lev-
els of background hybridization in both expanded and
condensed lobuloalveoli (Fig. 3, C, E, and G, arrows and
asterisks, respectively). With antisense probe, equivalent
high levels of b-casein RNA expression was observed in
both the normal and ErbB4DIC-expressing lobuloalveoli
(Fig. 3 D, arrow and asterisks, respectively). However, the
ErbB4DIC-expressing lobuloalveoli showed a moderate
diminution in WAP expression (Fig. 3 F). Strikingly, a-lac-
talbumin expression was reduced to sense probe back-
ground levels in condensed areas, but not in normal areas
of the same section (Fig. 3 H). The decrease in WAP and
the absence of a-lactalbumin expression suggests that ter-
minal differentiation in ErbB4DIC-expressing lobuloalve-
olar epithelium has been disrupted. Similar in situ hybrid-
ization analysis performed on mammary glands from
female mice at 1-d postpartum yielded equivalent levels of
expression of these genes in transgenic and nontransgenic
sisters (data not shown).
Stat5 Localized to the Nucleus of ErbB4DIC-expressing 
Mammary Epithelium Is Not Phosphorylated at Y694
The condensed lobuloalveoli and pattern of impaired milk
gene expression observed in ErbB4DIC-expressing mam-
mary tissue resembles mammary defects observed in mice
with Stat5 gene disruptions (Liu et al., 1996b; Teglund et
al., 1998). Stat5 expression was determined by immuno-
histochemistry in sections of mammary glands at 12-d
postpartum, containing both normal (Fig. 4 A) and ErbB4-
DIC-expressing lobuloalveoli (Fig. 4 D). Strong immuno-
staining was detected in the nuclei of both normal (compare
Fig. 4, B and C) and ErbB4DIC-expressing lobuloalveoli
(compare Fig. 4, E and F).
Since functional Stat5 is phosphorylated at Y694 (re-
viewed in Groner and Gouilleux, 1995), we used an anti-
body specific for Stat5 phosphorylated at Y694 to evaluate
the phosphorylation state of Stat5 (Fig. 5). Strong nuclear
staining and moderate cytoplasmic staining of phosphory-
lated Stat5 was detected within normal lobuloalveolar epi-
thelium at 12-d postpartum (Fig. 5 C). Immunoreactivity
was blocked by preadsorption with the peptide immunogen
(Fig. 5 B) and was undetectable in sections incubated with
affinity-purified rabbit IgG control primary antibody (data
not shown). Immunoreactive Stat5 and Phospho-Stat5 were
detected in both normal mammary glands and phenotypi-
cally normal areas of transgenic mammary glands at 1-, 3-,
6-, 9-, and 15-d postpartum, but not at day 18 (data not
shown). However, at day 12 postpartum, Stat5 was localized
to the nucleus, but not phosphorylated in areas expressing
ErbB4DIC (Fig. 5 F). The lack of Y694 phosphorylation of
nuclear Stat5 in ErbB4DIC-expressing lobuloalveolar epi-
thelium suggests that it is functionally inactive.
Figure 2. Immunohistochemical detection of ErbB4DIC protein
in the mammary gland at 12-d postpartum. Paraffin-embedded
section from a 12-d-postpartum nontransgenic sibling control
stained with hematoxylin/eosin (A). Sequential sections (B–D)
from a 12-d-postpartum mammary gland from an ErbB4DIC-
expressing mouse were stained with hematoxylin/eosin (B), or
stained by immunohistochemistry with rabbit IgG control anti-
body (C) or a rabbit anti-Flag antibody (D). Expanded secretory
lobuloalveoli are indicated by arrows, and condensed atypical
lobuloalveoli are indicated by asterisks. Bar in C, 100 mm.The Journal of Cell Biology, Volume 147, 1999 82
ErbB4 and Stat5 Interaction and ErbB4 Mediated 
Phosphorylation of Stat5 at Y694 Requires a Functional 
Stat5 SH2 Domain
Since expression of ErbB4DIC appears to inhibit phos-
phorylation of Stat5 at the regulatory site Y694, it is possi-
ble that ErbB4 normally regulates this effector protein
during mammary development. To determine if ErbB4
can induce phosphorylation of Stat5a at this site, the pro-
teins were ectopically expressed at high levels in human
embryonic kidney 293T cells (Fig. 6). Despite high levels
Figure 3. In situ hybridiza-
tion analysis of milk protein
gene expression in ErbB4DIC-
expressing mammary glands
at 12-d postpartum. Sequen-
tial sections from a 12-d-post-
partum mammary gland
from an ErbB4DIC-express-
ing mouse were stained with
hematoxylin/eosin (A) or
stained by immunohisto-
chemistry with anti-Flag anti-
body (B). Additional sequen-
tial sections were analyzed by
in situ hybridization with
b-casein sense (C) or anti-
sense (D) riboprobes, WAP
sense (E) or antisense (F) ri-
boprobes, or a-lactalbumin
sense (G) or antisense (H) ri-
boprobes. Expanded sec-
retory lobuloalveoli are in-
dicated by arrows and
condensed  atypical lobuloal-
veoli are indicated by aster-
isks. Bar in G, 100 mm.Jones et al. ErbB4 Activates Stat5 during Lactation 83
of Stat5a expression in transfected cell lysates (Fig. 6 H,
lanes 9 and 10, open circle), significant Stat5a tyrosine
phosphorylation was observed only when Stat5a was coex-
pressed with ErbB4 (Fig. 6 E, lane 10, open circle). This
phosphorylation included Y694, since it was detected by
the anti-Stat5 phospho-Y694 antibody (Fig. 6 G, lane 10).
When Stat5a and ErbB4 were coexpressed in 293T cells,
they could be cross-coimmunoprecipitated (Fig. 6 D, lane
4, E and F, lane 10). Stat5a coimmunoprecipitated with
anti-ErbB4 (Fig. 6 D, lane 4) and was not phosphorylated
at Y694 (Fig. 6 C, lane 4), suggesting that phosphorylation
of Stat5a results in rapid release of Stat5a from an ErbB4/
Stat5a complex.
To determine the specificity of ErbB4/Stat5a interaction
and ErbB4-mediated phosphorylation of Stat5a on Y694,
293T cells were transfected with mutant STAT5a alleles,
with inactivating mutations in the SH2 domain (R618 to
V) or at Y694 (Y to F). The two Stat5a mutants were ex-
pressed at levels comparable to wild-type Stat5a (Fig. 6 H,
compare lanes 9 and 10 to 11 and 12), but the Stat5a mu-
tants were not phosphorylated at Y694 when coexpressed
with ErbB4 (Fig. 6 G, lanes 11 and 12). Interestingly, the
Figure 4. Immunohistochem-
ical detection of Stat5 protein
in ErbB4DIC-expressing mam-
mary glands at 12-d postpar-
tum. High magnification pho-
tomicrographs of expanded
lobuloalveoli lacking detect-
able ErbB4DIC expression
(A–C) or a different region of
the same section containing
condensed lobuloalveoli ex-
pressing high levels of
ErbB4DIC protein (D–F).
Sections were stained with
hematoxylin/eosin (A and
D), or stained by immunohis-
tochemistry with rabbit se-
rum negative control (B and
E) or rabbit anti-Stat5 (C and
F). Bar in D, 30 mm.
Figure 5. Immunohistochem-
ical detection of Stat5
phosphorylated at Y694 in
ErbB4DIC-expressing mam-
mary glands at 12-d postpar-
tum. High magnification rep-
resentations of expanded
lobuloalveoli lacking detect-
able ErbB4DIC expression
(A–C) or a different region
of the same section contain-
ing condensed lobuloalveoli
expressing high levels of
ErbB4DIC protein (D–F).
Sections were stained with
hematoxylin/eosin (A and
D), or stained by immuno-
histochemistry with anti-
phospho-Stat5 antibody pre-
adsorbed with peptide
immunogen and counter-
stained with methyl green (B
and E), or phospho-Stat5 an-
tibody without counterstain
(C and F). Bar in D, 30 mm.The Journal of Cell Biology, Volume 147, 1999 84
Stat5a Y694F mutant was tyrosine phosphorylated at sites
other than Y694 when coexpressed with ErbB4 (Fig. 6 E,
lane 12). Alternative tyrosine phosphorylation of the
Stat5a Y694F mutant also has been observed in 293T cells
when cotransfected with a T cell receptor and Lck tyro-
sine kinase (Welte, T., and X.-Y. Fu, unpublished obser-
vations), and with activation of the EGFR (Olayioye et
al., 1999). When expressed alone, the Stat5a mutants
Y694F and SH2 were not immunoprecipitated by ErbB4-
specific antiserum (data not shown). In summary, ErbB4
and Stat5a were coimmunoprecipitated when coexpressed
(Fig. 6 D, lane 6; E, closed circle, lane 12; and F, lane 12,
respectively) and the Stat5a SH2 domain mutation pre-
vented association of ErbB4 and Stat5a (Fig 6 D, lane 5, E
and F, lane 11). Hence, the interaction between activated
ErbB4 and Stat5a, and subsequent tyrosine phosphoryla-
tion of Stat5a at Y694, requires a functional Stat5a SH2
domain.
Discussion
Members of the EGFR family have important functions
during several stages of mammary gland development.
Stromal expression of EGFR is required for ductal mor-
phogenesis (Sebastian et al., 1998; Wiesen et al., 1999).
Epithelial functions for the receptors are suggested by the
patterns of expression of ligands and receptors (Schroeder
and Lee, 1998), by the functional effects of hormone im-
plants (Vonderhaar, 1987; Coleman et al., 1988; Jones et al.,
1996; Kenney et al., 1996), and by the phenotypes of
MMTV-driven transgenic animals expressing dominant-
negative receptor genes (Xie et al., 1997; Jones and Stern,
1999).
To elucidate the function of ErbB4 during mouse mam-
mary gland development, we inactivated ErbB4 signaling
in the developing mouse mammary gland through the di-
rected expression of dominant-negative ErbB4 as a trans-
gene. Despite significant levels of transgene expression
throughout pregnancy and even greater levels of expres-
sion early postpartum, an ErbB4DIC-specific phenotype
was not observed until mid-lactation at 12-d postpartum.
Lobuloalveoli expressing ErbB4DIC at 12-d postpartum
were condensed, with lumens predominantly filled with
secretory lipids, a phenotype resembling normal tissue at
late pregnancy. Furthermore, the ErbB4DIC-expressing
lobuloalveoli failed to terminally differentiate, as evi-
denced by a lack of a-lactalbumin expression. ErbB4DIC
also inhibited Stat5 phosphorylation at Y694, suggesting
that Stat5 is an important downstream mediator of ErbB4
signaling during lactation.
The ErbB4DIC phenotype is significantly different from
the phenotypes observed in transgenic mice harboring
MMTV-driven dominant-negative EGFR or ErbB2 (Xie
et al., 1997; Jones and Stern, 1999). Dominant-negative
EGFR inhibited ductal morphogenesis in the pubescent
virgin mouse. The dominant-negative receptor did not
have an effect, however, during pregnancy or lactation, ap-
parently because of high levels of endogenous EGFR ex-
pression during these developmental stages. In contrast,
the dominant-negative MMTV-ErbB2DIC did not affect
virgin mammary gland development, but did inhibit lobu-
loalveolar development at parturition (Jones and Stern,
1999). This phenotype appears earlier than the ErbB4DIC
phenotype described here, and is not accompanied by sup-
pression of mRNA for WAP, or a-lactalbumin (Jones, F.,
unpublished data). Although the dominant-negative re-
ceptors have some ability to inactivate heterologous di-
merization partners in vitro, the nonoverlapping pheno-
types obtained with dominant-negative EGFR, ErbB2,
and ErbB4 suggests that each of these dominant-negative
receptors does not act as a pan–dominant-negative.
Corroborative evidence supporting a role for ErbB4 sig-
naling during mid-lactation comes from the timing of
ErbB4 activation during mouse mammary gland develop-
ment, since ErbB4 tyrosine phosphorylation is dramati-
cally enhanced at 14-d postpartum (Schroeder and Lee,
1998). These results support the conclusion that ErbB4
signaling plays an important role in lobuloalveolar mainte-
nance and lactation during mid-lactation.
Additional members of the EGFR family and their
ligands have been implicated in lobuloalveolar develop-
Figure 6. Coexpression of ErbB4 and Stat5a. 293T cells were
transfected with various combinations of ErbB4 and Stat5 ex-
pression vectors and lysates of transfected cells were prepared 48 h
posttransfection, as described in Materials and Methods. Immu-
noprecipitations were performed using ErbB4-specific (A–D) or
Stat5-specific (E–H) antibodies. Immunoprecipitates were re-
solved by SDS-PAGE and the 7.5% acrylamide resolving gel was
transferred to nitrocellulose. Western blot analysis was per-
formed using antibodies to detect tyrosine phosphorylated pro-
teins (A and E), ErbB4 (B and F), phospho-Stat5 (C and G), or
Stat5 (D and H). Stat5 mutants were Stat5/R618V, a point muta-
tion which ablates SH2 function, and Stat5/Y694F, which elimi-
nates the regulatory Y694. Transfections were with empty vec-
tors (lanes 1 and 7), ErbB4 alone (lanes 2 and 8), Stat5a alone
(lanes 3 and 9), ErbB4 1 Stat5a (lanes 4 and 10), ErbB4 1 Stat5/
R618V (lanes 5 and 11), and ErbB4 1 Stat5/Y694F (lanes 6 and
12). Closed circles in A and E indicate the position of ErbB4 at
z190 kD; open circles in D, E, and H indicate the position of
Stat5a at z95 kD.Jones et al. ErbB4 Activates Stat5 during Lactation 85
ment and lactation. Our in vivo experiments identified a
role for ErbB2 signaling in lobuloalveolar development at
parturition (Jones and Stern, 1999). Similarly, activated
ErbB2 induces the formation of alveolar-like structures in
a mammary epithelial cell culture system (Niemann et al.,
1998). Waved-2 mice, which carry a spontaneous point
mutation within the EGFR kinase domain, have reduced
EGFR kinase activity and exhibit impaired lobuloalveolar
development and decreased lactation (Fowler et al., 1995).
The ErbB3 and ErbB4 ligand, NRG1, is required for lobu-
loalveolar development in mammary organ cultures (Yang
et al., 1995) and can induce lobuloalveoli formation and
lactation when encapsulated and implanted within mam-
mary glands of virgin mice (Jones et al., 1996). In addition,
mice lacking the EGFR ligand amphiregulin develop im-
mature lobuloalveoli, and the cumulative loss of EGF and
TGFa aggravates this defect (Luetteke et al., 1999). Over-
lapping expression and activation of ErbB4 with EGFR
and ErbB2 during lobuloalveolar development (Schroeder
and Lee, 1998) suggests that ErbB4 activity at this devel-
opmental stage may be regulated by these receptors and
the aforementioned ligands with functions during lobu-
loalveolar development.
The ErbB4DIC-expressing mammary epithelium resem-
bles the phenotype observed in mice with a disrupted
Stat5a gene (Liu et al., 1996b; Teglund et al., 1998). ErbB4
signaling during mid-lactation is required for Stat5 activa-
tion, since Stat5 expressed in ErbB4DIC-expressing lobu-
loalveoli was not phosphorylated on the regulatory Y694.
Phosphorylation of this residue is essential for some Stat5
functions including dimerization and DNA binding (Gro-
ner and Gouilleux, 1995). To our knowledge, this is the
first in vivo evidence that an EGFR family member can
mediate activation of Stat5. Surprisingly, Stat5 lacking
phosphorylation at Y694 was localized to the nucleus of
ErbB4DIC expressing lobuloalveolar epithelium. The cur-
rent paradigm is that Stat5 phosphorylation at Y694 and
subsequent dimerization are essential for Stat5 nuclear lo-
calization (Groner and Gouilleux, 1995). However, this
may not always be the case. It is conceivable that Stat is
imported to the nucleus in a complex with the ligand-acti-
vated progesterone receptor (Richer et al., 1998). John-
son and coworkers have observed EGF-induced nuclear
translocation of nonphosphorylated Stat2 (Johnson et
al., 1999). These recent observations, along with our re-
sults, demonstrate that nuclear translocation of Stat pro-
teins, mediated by activation of EGFR family members,
can occur in the absence of Stat tyrosine phosphorylation
at Y694. Others have detected ErbB4 within the nucleus
of breast epithelium (Gullick and Srinivasan, 1998), and
nuclear translocation of exogenous ErbB4 ligand, NRG1,
has been reported (Li et al., 1996). These results raise the
possibility that Stat5 may be transported to the nucleus in
a complex with ligand-bound receptor. A similar mecha-
nism has been proposed for Stat nuclear translocation me-
diated by ligand-activated interferon g receptor (Johnson
et al., 1998).
The coupling of ErbB4 to Stat5 regulation is reinforced
by a survey of the ability of ErbB family receptor combi-
nations to regulate Stats (Olayioye et al., 1999). NRG1
stimulated Tyr phosphorylation and activation of Stat5b in
fibroblasts coexpressing ErbB2 and ErbB4, but not fibro-
blasts coexpressing EGFR and ErbB4, or ErbB2 and
ErbB3. NRG1 is expressed at moderate levels during lac-
tation (Schroeder and Lee, 1998), suggesting a means for
activation of Stat5.
In transient transfection assays, ErbB4 induced phos-
phorylation of Stat5a on Y694, and the two proteins could
be coprecipitated in a Stat5 SH2-dependent manner. This
suggests that Stat5 is a direct substrate for ErbB4, al-
though we cannot rule out the possible recruitment of a
second tyrosine kinase into the complex. Indeed, c-src is
an important mediator of Stat5a activation by ErbB family
members, and Janus kinases (JAKs) can associate stably
with these receptors (Olayioye et al., 1999). The COOH-
terminal portion of ErbB4, which contains tyrosine auto-
phosphorylation sites, is required for ErbB4 and Stat5a
coimmunoprecipitation (data not shown). The Stat5 con-
sensus docking site (YZXZ, where Z represents a hydro-
phobic residue; May et al., 1996), is present at three sites
within the COOH terminus of ErbB4, raising the possibil-
ity of a direct interaction between Stat5 and ErbB4.
Activation of Stat5 during lactation is thought to be me-
diated by prolactin receptor (PrlR) signaling (reviewed in
Hennighausen et al., 1997). In the rodent mammary gland,
PrlR is expressed as long (LPrlR) and short (SPrlR) iso-
forms (Boutin et al., 1988; Davis and Linzer, 1989; Shirota
et al., 1990). Only the LPrlR can activate Stat5 to stimulate
b-casein promoter activity (Lesueur et al., 1991). More-
over, SPrlR acts as a dominant-negative and interferes
with  b-casein promoter induction by LPrlR (Berlanga et al.,
1997). Expression of the two PrlR isoforms is differentially
regulated during mammary development, resulting in an
increase in the ratio between SPrlR and LPrlR as lactation
progresses (Jahn et al., 1991; Nagano and Kelly, 1994; Mi-
zoguchi et al., 1997). The formation of inactive SPrlR/
LPrlR heterodimers would, therefore, increase during lac-
tation. One possible function of ErbB4 signaling in the
mouse mammary gland would be maintenance of Stat5 ac-
tivation at mid-lactation and compensation for the poten-
tial diminution in PrlR signaling activity. Another possibil-
ity is based upon the mechanistic differences between
EGFR and PrlR regulation of Stat5 (Olayioye et al., 1999).
c-Src is required for coupling of EGFR, but not PrlR to
Stat5, and, conversely, Jak2 is required for coupling of
PrlR, but not EGFR to Stat5. Moreover, EGFR (Olayioye
et al., 1999) and ErbB4 (see above) induce additional Tyr
phosphorylation in Stat5 besides Y694. Hence, the down-
stream targets and adaptor functions of Stat5 may be dif-
ferent when regulated by receptor kinases or by cytokine
receptors, so that Stat regulation by these two afferent sys-
tems is not functionally redundant.
In contrast to expression of the other EGFR family
members, expression of ErbB4 in breast cancer is associ-
ated with favorable prognosis (Bacus et al., 1994, 1996;
Knowlden et al., 1998) and a differentiating tumor phe-
notype (Srinivasan et al., 1998). In this communication,
we present in vivo evidence demonstrating a role for
ErbB4 signaling in terminal differentiation of mammary
epithelial cells. Our results raise the intriguing possibil-
ity that ErbB4 activity in breast cancer cells may acti-
vate differentiation pathways and thus antagonize the
oncogenic properties of other coexpressed EGFR family
members.The Journal of Cell Biology, Volume 147, 1999 86
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